dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Grothey, Axel |
dc.contributor.author | Van Cutsem, Eric |
dc.contributor.author | Wasan, Harpreet |
dc.contributor.author | Tabernero Caturla, Josep |
dc.contributor.author | Yoshino, Takayuki |
dc.contributor.author | Yaeger, Rona |
dc.contributor.author | Kopetz, Scott |
dc.date.accessioned | 2022-09-08T11:49:53Z |
dc.date.available | 2022-09-08T11:49:53Z |
dc.date.issued | 2022-06 |
dc.identifier.citation | Kopetz S, Grothey A, Van Cutsem E, Yaeger R, Wasan H, Yoshino T, et al. Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC. ESMO Open. 2022 Jun;7(3):100477. |
dc.identifier.issn | 2059-7029 |
dc.identifier.uri | https://hdl.handle.net/11351/8077 |
dc.description | Càncer colorectal; Encorafenib; Qualitat de vida |
dc.description.sponsorship | This study was sponsored by Array BioPharma Inc, which was acquired by Pfizer, United States; National Cancer Institute, United States in July 2019. This work was also supported by the Cancer Center Core Grant [grant number P30 CA 008748] to Memorial Sloan-Kettering Cancer Center. |
dc.language.iso | eng |
dc.publisher | Elsevier |
dc.relation.ispartofseries | ESMO Open;7(3) |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.source | Scientia |
dc.subject | Còlon - Càncer - Tractament |
dc.subject | Recte - Càncer - Tractament |
dc.subject | Avaluació de resultats (Assistència sanitària) |
dc.subject.mesh | Colorectal Neoplasms |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Antineoplastic Combined Chemotherapy Protocols |
dc.subject.mesh | Patient Reported Outcome Measures |
dc.title | Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1016/j.esmoop.2022.100477 |
dc.subject.decs | neoplasias colorrectales |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | protocolos de quimioterapia antineoplásica combinada |
dc.subject.decs | medidas de resultados percibidos por los pacientes |
dc.relation.publishversion | https://doi.org/10.1016/j.esmoop.2022.100477 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Kopetz S] University of Texas MD Anderson Cancer Center, Houston, USA. [Grothey A] West Cancer Center and Research Institute, OneOncology, Germantown, USA. [Van Cutsem E] University Hospitals Gasthuisberg Leuven and KU Leuven, Leuven, Belgium. [Yaeger R] Memorial Sloan-Kettering Cancer Center, New York, USA. [Wasan H] Hammersmith Hospital, Department of Cancer Medicine, London, UK. [Yoshino T] National Cancer Center Hospital East, Kashiwa, Japan. [Tabernero J] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. IOB-Quiron, UVic-UCC, Barcelona, Spain |
dc.identifier.pmid | 35653981 |
dc.identifier.wos | 000836447200008 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |